How SARS-CoV-2 mRNA vaccines affect immune responses
Regulation of germinal center responses by SARS-CoV-2 messenger RNA vaccines
This study is looking at how mRNA vaccines for COVID-19 help your body build a strong and lasting immune response, focusing on how certain immune cells work together to create effective antibodies, and it includes both mice and people to see how long this protection lasts.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11012782 on NIH RePORTER |
What this research studies
This research investigates how messenger RNA (mRNA) vaccines for SARS-CoV-2 induce immune responses in the body, focusing on the formation and durability of germinal centers, which are crucial for producing effective antibodies. The study aims to understand the mechanisms behind the immune response, including how different immune cells interact during vaccination. By examining both mice and human responses, the research seeks to uncover the longevity of these immune reactions and the role of specific cells in promoting effective immunity.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals who have received SARS-CoV-2 mRNA vaccines and are interested in understanding their immune response.
Not a fit: Patients who have not been vaccinated against SARS-CoV-2 or those with certain immune deficiencies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved vaccine strategies that enhance long-term immunity against COVID-19.
How similar studies have performed: Other research has shown promising results in understanding immune responses to mRNA vaccines, making this approach both relevant and potentially impactful.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Locci, Michela — University of Pennsylvania
- Study coordinator: Locci, Michela
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.